"higher efficacy"

#6558232

25 March 2021

A nurse holds a vial of AstraZeneca COVID-19 vaccine at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558230

25 March 2021

A nurse fills a syringe with a vial of AstraZeneca COVID-19 vaccine at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558228

25 March 2021

A nurse fills a syringe with a vial of AstraZeneca COVID-19 vaccine at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558226

25 March 2021

A nurse holds a vial of AstraZeneca COVID-19 vaccine at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558224

25 March 2021

A nurse fills a syringe with a vial of AstraZeneca COVID-19 vaccine at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558222

25 March 2021

A nurse fills a syringe with a vial of AstraZeneca COVID-19 vaccine at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558220

25 March 2021

A nurse shows a vial of AstraZeneca COVID-19 vaccine for photographers during a press event at the Military Institure of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558218

25 March 2021

A nurse grabs a vial of AstraZeneca COVID-19 vaccine at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558216

25 March 2021

A vial of AstraZeneca COVID-19 vaccine is seen at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558214

25 March 2021

A vial of AstraZeneca COVID-19 vaccine is seen at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#6558212

25 March 2021

A vial of AstraZeneca COVID-19 vaccine is seen at the Military Institute of Medicine in Warsaw, Poland on March 25, 2021. AstraZeneca announced on Monday in a press release that its adenovirus vector-based vaccine demonstrated 79 percent efficacy preventing symptomatic Covid-19 and 100 percent efficacy in preventing death and hospitalization. The data released comes after a public rebuke from the National Institutes of Health concerning how AstraZeneca presented some of its older results showing higher efficacy earlier this week.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.